Home / Market News / $TPST
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

Tempest Therapeutics Appoints Stephanie Horn-Warnock as CFO

Nov 1, 2026, 2:04 PM UTC · Primary ticker $TPST

Tempest Therapeutics announced a change in its executive leadership, appointing Stephanie Horn-Warnock as the new CFO, Treasurer, and Corporate Secretary. This transition follows the immediate resignation of Constance Ames for personal reasons, signaling a moderate but notable shift in the company's financial leadership.

Tempest Therapeutics has appointed Stephanie Horn-Warnock as its new Chief Financial Officer, Treasurer, and Corporate Secretary, replacing Constance Ames who resigned for personal reasons. This change in financial leadership is a moderate corporate catalyst. While a CFO change can sometimes signal underlying issues or a new strategic direction, the filing explicitly states the previous CFO's departure was for personal reasons, mitigating immediate negative implications. Horn-Warnock's extensive experience in healthcare and pharmaceuticals suggests a continuity of financial expertise. For traders, the short-term impact is likely neutral, as the company maintains experienced financial oversight. Long-term implications depend on Horn-Warnock's strategic contributions, but the immediate risk of leadership instability is low given the stated reasons for the transition.

$TPST neutral CFO appointment
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.